🇺🇸 FDA
Patent

US 7157495

Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor

granted A61PA61P31/00A61P31/12

Quick answer

US patent 7157495 (Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Dec 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jan 02 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
51
CPC classes
A61P, A61P31/00, A61P31/12, A61P31/14, A61P31/18